SCHEMBL5260759

SCHEMBL5260759

CNc1ncnc(-c2cccnc2Oc2ccc(F)c(C(=O)Nc3cc(OC[C@]4(C)CCCN4)cc(C(F)(F)F)c3)c2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 19/20 0.60
KDR P35968 15/20 0.56
EGFR P00533 2/20 0.56
LCK P06239 2/20 0.56
IGF1R P08069 2/20 0.56
MET P08581 2/20 0.56
SRC P12931 2/20 0.56
ZAP70 P43403 2/20 0.56
MAPK10 P53779 2/20 0.56
BTK Q06187 2/20 0.56
MAPK14 Q16539 2/20 0.56
AURKA O14965 1/20 0.56
ABL1 P00519 1/20 0.56
NTRK1 P04629 1/20 0.56
INSR P06213 1/20 0.56
FES P07332 1/20 0.56
CSF1R P07333 1/20 0.56
LYN P07948 1/20 0.56
RET P07949 1/20 0.56
PDGFRB P09619 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264769 0.88 TEK (0.67) TEKKDREGFRLCKIGF1R
SCHEMBL5264044 0.83 TEK (0.58) TEKKDRLCKSRCMAPK14
SCHEMBL5260763 0.83 TEK (0.63) TEKKDREGFRLCKIGF1R
SCHEMBL1265162 0.83 TEK (0.63) TEKKDREGFRLCKIGF1R
SCHEMBL1264141 0.82 TEK (0.71) TEKKDREGFRLCKIGF1R
SCHEMBL5262860 0.81 TEK (0.52) TEKKDRLCKSRCMAPK14
SCHEMBL5262308 0.81 TEK (0.54) TEKKDRLCKSRCMAPK14
SCHEMBL5261499 0.80 TEK (0.67) TEKKDRLCKSRCMAPK14
SCHEMBL1265197 0.79 TEK (0.68) TEKKDREGFRLCKIGF1R
SCHEMBL5261770 0.79 TEK (0.59) TEKKDRLCKSRCMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751136-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2007-02-14 EP claimed
WO-2005113494-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2005-12-01 WO claimed